ABL Diagnostics says ABL stake falls below 95% to 93.58%

The move advances a free-float expansion plan outlined in the 2022 AMF-approved prospectus, while ABL said it remains the company’s clear majority shareholder.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.